PMID- 18055567
OWN - NLM
STAT- MEDLINE
DCOM- 20080204
LR  - 20080123
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 37
IP  - 12
DP  - 2007 Dec
TI  - Successful treatment of primary plasma cell leukaemia by allogeneic stem cell 
      transplantation from haploidentical sibling.
PG  - 969-72
AB  - Primary plasma cell leukaemia (PCL) is a rare, aggressive neoplasm of plasma cell 
      dyscrasia. Conventional chemotherapy is usually ineffective, with an overall 
      survival of only 8 months. Here, we describe a 42-year-old man with primary PCL, 
      who was successfully treated with haploidentical (2-HLA loci mismatched) 
      haematopoietic stem-cell transplantation (HSCT). To overcome the human leukocyte 
      antigen (HLA) disparity, in vivo T-cell purging by the pre-transplant 
      administration of antithymocyte globulin followed by a conventional prophylactic 
      treatment against graft-versus-host disease (GVHD) resulted in an avoidance of 
      severe GVHD as well as infectious complications. The patient has maintained 
      complete remission for 13 months after haploidentical HSCT, indicating that a 
      graft-versus-PCL effect might be preserved. Haploidentical HSCT can be a 
      potentially curative treatment for patients with primary PCL who do not have an 
      HLA-identical donor.
FAU - Nonami, Atsushi
AU  - Nonami A
AD  - First Department of Internal Medicine, Graduate School of Medicine, Kyushu 
      University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 
      anonamin@yahoo.co.jp
FAU - Miyamoto, Toshihiro
AU  - Miyamoto T
FAU - Kuroiwa, Mika
AU  - Kuroiwa M
FAU - Kunisaki, Yuya
AU  - Kunisaki Y
FAU - Kamezaki, Kenjiro
AU  - Kamezaki K
FAU - Takenaka, Katsuto
AU  - Takenaka K
FAU - Harada, Naoki
AU  - Harada N
FAU - Teshima, Takanori
AU  - Teshima T
FAU - Harada, Mine
AU  - Harada M
FAU - Nagafuji, Koji
AU  - Nagafuji K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071130
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Antilymphocyte Serum/administration & dosage
MH  - Bone Marrow Purging
MH  - Graft vs Host Disease/prevention & control
MH  - *Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage
MH  - Leukemia, Plasma Cell/genetics/*surgery
MH  - Male
MH  - *Siblings
MH  - T-Lymphocytes
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2007/12/07 09:00
MHDA- 2008/02/05 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2008/02/05 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - hym130 [pii]
AID - 10.1093/jjco/hym130 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2007 Dec;37(12):969-72. doi: 10.1093/jjco/hym130. Epub 2007 Nov 
      30.